hrp0095p1-154 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Reference values in pelvic ultrasonography for a Spanish population of healthy girls between 6 and 12 years old

Corripio Raquel , Villalobos Marisa , Patricia Beltrán-Salazar Viviana , Pérez Jacobo , Duran Carmina

Background: Pelvic ultrasonography (PUS) of the uterus and ovaries allows the diagnosis of changes in sexual development. However, the reference values used in Spain originate from old studies conducted in other countries.Objective: To determine reference uterine and ovarian measurements by PUS and according to pubertal status and bone age in a Spanish population of healthy girls aged between 6 and 12 years.<p class=...

hrp0092p1-382 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Nutritional Requirements in Prader Willi Syndrome Children Treated with Growth Hormone Under Two Years of Age

Corripio Raquel , Franch Noemi , Couto Yolanda , Pérez Jacobo , Gabau Elisabeth , Capdevila Nuria , Rivera Josefa

Background: Prader Willi Syndrome (PWS) patients under treatment with growth hormone (GH) have a better body composition and cognitive performance than untreated patients. The 2013 guideline recommended to start this treatment as soon as possible, for that reason 14 toddlers have been included in our center. Classically a 25% decrease in the caloric intake of PWS patients has been recommended to avoid obesity. However, from clinical practice observation, w...

hrp0089p1-p166 | Growth &amp; Syndromes P1 | ESPE2018

Safety and Effectiveness of Growth Hormone Treatment in Patients with Prader-Willi Syndrome under 2 Years of Age in a Reference Hospital

Corripio Raquel , Tubau Carla , Cahis Nuria , Perez Jacobo , Rivera Josefa , Gabau Elisabeth

Introduction: Growth hormone (GH) treatment was approved in 2000 for patients with Prader-Willi syndrome (PWS). The main reason for its use was the improvement in body composition. As a result of 2 fatal episodes, it was decided to initiate it from 2 years of age arbitrarily. Average age of real start: 4-6years. GH per se is not a risk factor for mortality in PWS. The 2013 guideline recommends to star it as soon as possible, preferably under 2 years of age, when obesity is est...

hrp0089p2-p245 | Growth &amp; Syndromes P2 | ESPE2018

Clinical Review of Seven Patients Affected with 49,XXXXY Syndrome

Sanchez Jacobo Perez , Collado Raquel Corripio , Escofet Concepcion , Brun Carme , Gabau Elisabeth

Introduction: 49,XXXXY polysomy incidence is about 1 per 85000 to 100000 male births. As a rare condition with medical problems affecting different systems it should be evaluated under a multidisciplinary approach. We have reviewed the clinical characteristics of patients with this anomaly from all the country who contacted the program for evaluation.Methods: In 2016 we started a multidisciplinary program for the care of patients with sex chromosomal ane...

hrp0084p2-170 | Adrenals | ESPE2015

Usefulness of Salivary Cortisol Levels in Secondary Adrenal Insufficiency in Paediatric Population

Corripio Raquel , Perez Jacobo , Borras Ariadna , Capdevila Laura , Sanchez Judith , Rivera Josefa

Background: The main cause of secondary adrenal insufficiency (SAI) in children is prolonged treatment with exogenous corticosteroids. plasma cortisol (PC) levels after administration of ACTH is the most used indicator of adrenal function in clinical practice. However, salivary cortisol (SC) levels is emerging as an alternative technique in the diagnosis of adrenal pathology, especially useful in the paediatric population because it is a simple noninvasive test.<p class="a...

hrp0084p3-699 | Diabetes | ESPE2015

Continuous Intersticial Glucose Monitoring in Early Detection of Glucose Tolerance Abnormalities in Adolescents with Cystic Fibrosis

Perez Jacobo , Corripio Raquel , Belver David , Asensio Oscar , Bosque Montserrat , Rivera Josefa

Background: Cystic fibrosis-related diabetes (CFRD) and glucose abnormalities have a negative impact on pulmonary function and survival in cystic fibrosis (CF) patients. Oral glucose tolerance test (OGGT) is the screening test of choice for CFRD, although undetected high glucose levels can be missed with this test. The use of a continuous intersticial fluid glucose monitoring system (CGM) can be useful in these patients.Objective and hypotheses: To deter...

hrp0094p2-197 | Fat, metabolism and obesity | ESPE2021

Triponderal mass index for the categorisation of childhood obesity on the basis of 58.364 observations of 7.792 patients

Corripio Raquel , Alder Lorna , Perez Jacobo , Sanchez-Garvin Dunia , Rivera Josefa ,

Introduction: childhood obesity constitutes a relevant problem of public health. Body mass index (BMI) is the most used anthropometric parameter for its definition: >2 z-score deviation (SD) according to age and sex for reference charts. Recent studies have proposed triponderal mass index (TMI) to identify metabolic risk by obesity. TMI presents the advantage to be a constant value simplifying the calculations.Aims: determine the use...

hrp0094p2-288 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Comorbidities in Turner Syndrome patients controlled in our center since the 80’s

Corripio Raquel , Vargas Laura , Baena Neus , Garcia Emma , Perez Jacobo , Rivera Josefa ,

Introduction: Turner syndrome (TS) is a genetic condition with different phenotypic expressions depending on karyotype. Due to genetic prenatal testing, its prevalence is getting lower. The objective was to analyze the presence of different comorbidities associated with TS according to the karyotype and evaluate if there is follow-up in adulthood.Methods: Descriptive retrospective study including all the patients genetic...

hrp0092fc15.5 | Late Breaking Abstracts | ESPE2019

Effects of Bifidobacterium animalis subsp. lactis on Children with Prader-Willi Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

Ramon-Krauel Marta , Amat-Bou Montse , García-Rivera Sonika , Corripio Raquel , Ibáñez Lourdes , Lerin Carles

The gut microbiome has recently emerged as a major contributor to obesity and metabolic disease. Specifically, Bifidobacterium animalis sups. lactis (BAL) has shown promise for obesity treatment in human subjects, improving body composition and metabolic health. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome (PWS) include hyperphagia, ...

hrp0097p1-124 | Growth and Syndromes | ESPE2023

Caloric intake of 6 months-12 years old children with Prader Willi Syndrome under growth hormone treatment at a reference center.

Corripio Raquel , Couto Yolanda , Sánchez-Garvín Dunia , Pérez-Sánchez Jacobo , Garcia-Tirado Diana

Introduction: Prader-Willi Syndrome (PWS) is the most frequent cause of genetic obesity. It has been described that these patients require a reduction in caloric intake of 20- 40% compared to general population. Since 2000, with the approval of growth hormone (GH), the evolution of obesity has changed and it seems that caloric requirements could be different.Methodology: Observational, descriptive, cross-sectional and re...